Merck's human papillomavirus vaccine has been approved for men in China, it said on Wednesday, providing the U.S. drugmaker a ...

U.S. drugmaker Merck & Co said on Wednesday its human papillomavirus (HPV) vaccine for men has been approved by China's ...

China’s drug regulator approved Merck & Co.’s blockbuster HPV vaccine for use by men, opening a new untapped market for the ...

This was the stock's second consecutive day of gains.

Truist Financial analyst Srikripa Devarakonda downgraded Merck & Company (MRK – Research Report) to a Hold yesterday and set a price target ...

Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range ...

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows ...

Last Friday, the Medicines and Healthcare Products Regulatory Agency approved Merck & Co Inc’s (NYSE:MRK) Winrevair (sotatercept) for adult patients with pulmonary arterial hypertension (PAH).

WuXi Biologics’ move to sell the facility could strengthen the company’s cash flow and margins as it navigates global ...

Truist downgraded Merck (MRK) to Hold from Buy with a price target of $110, down from $130, as part of a broader research note previewing FY25 ...

Merck, a leading science and technology company, announced the closing of the transaction to acquire HUB Organoids Holding ...

U.S. drugmaker Merck & Co said on Wednesday its human papillomavirus (HPV) vaccine for men has been approved by China's ...